|1.||van Rooijen, Nico: 47 articles (12/2015 - 01/2002)|
|2.||Endo, Yasuo: 7 articles (01/2013 - 10/2005)|
|3.||Van Rooijen, Nico: 7 articles (05/2012 - 09/2002)|
|4.||van Rooijen, N: 7 articles (08/2008 - 05/2000)|
|5.||Coleman, Robert E: 7 articles (04/2006 - 12/2002)|
|6.||Morgan, Gareth J: 6 articles (07/2014 - 12/2010)|
|7.||Elomaa, I: 6 articles (08/2005 - 01/2001)|
|8.||Saarto, T: 6 articles (08/2005 - 01/2001)|
|9.||Rovetta, G: 6 articles (10/2003 - 01/2000)|
|10.||Monteforte, P: 6 articles (10/2003 - 01/2000)|
|1.||Neoplasm Metastasis (Metastasis)
12/01/2008 - "Significant reductions in the incidence of bony and visceral metastases and improvement in duration of DFS at 36- and 55-month follow-up periods were no longer seen with clodronate. "
08/01/2002 - "The occurrence of nonosseous metastases was similar (clodronate, n = 112; placebo, n = 128; P =.257), but there was a significant reduction in mortality (clodronate, n = 98; placebo, n = 129; P =.047) during the total follow-up period. "
08/01/2002 - "During the medication period there was a significant reduction in the occurrence of bone metastases (clodronate, n = 12; placebo, n = 28; HR, 0.44; 95% CI, 0.22 to 0.86; P =.016). "
01/01/2002 - "Adjuvant clodronate was found to be associated with a significant reduction in the incidence of bone metastases during the treatment period. "
08/01/1999 - "In addition, clodronate recipients had a significantly greater incidence of nonskeletal metastases (local and visceral), and significantly lower survival rates. "
06/01/1994 - "Short term intravenous administration (usually 300 mg/day for 5 days) or longer courses of oral clodronate (usually 1600 mg/day for 6 months) effectively reduced bone pain and/or improved mobility in most patients with Paget's disease, and these effects persisted for up to 12 months after discontinuing clodronate. "
02/01/2015 - "The improvements in Lequesne index, global KOA evaluation from both patients and investigators, and the WOMAC pain subscale were significantly greater in the clodronate group. "
01/01/2001 - "At the end of treatment, pain relief was significantly greater in patients treated with disodium-clodronate. "
12/01/1995 - "Clodronate is also effective in some patients in reducing bone pain and improving mobility. "
09/01/1995 - "Three of 27 patients continued to have relief from pain after 3 months of oral clodronate therapy. "
|3.||Breast Neoplasms (Breast Cancer)
08/01/1999 - "Currently, clodronate is probably most effective in the treatment and prevention of general skeletal complications in patients with breast cancer."
01/01/1992 - "Thus, clodronate seems to be a safe and highly efficacious drug for the treatment of hypercalcaemia in breast cancer patients."
01/01/2006 - "Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]."
06/01/2013 - "We performed a literature search to identify studies that investigated the effects of clodronate treatment on early breast cancer. "
06/01/2013 - "The aim of this study was to evaluate the effectiveness of clodronate in the adjuvant therapy of early breast cancer on patient survival. "
10/01/1995 - "Clodronate, a bisphosphonate, has been shown to be effective in the treatment of hypercalcaemia in patients with multiple myeloma. "
10/31/1992 - "We conclude that clodronate is an effective and safe adjunct in the management of multiple myeloma. "
06/01/2001 - "The original analysis of this study shows that there is a benefit in taking 1600 mg clodronate daily for patients with myelomatosis to prevent the development of new skeletal disease. "
06/01/2001 - "Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma."
02/01/1998 - "The study indicates that long-term oral clodronate slows the progression of skeletal disease in multiple myeloma and decreases the associated morbidity. "
|5.||Hypercalcemia (Milk Alkali Syndrome)
01/01/1989 - "Chloromethanediphosphonate (Cl2MDP), a cation chelator, is used as a therapeutic for hypercalcemia of malignancy. "
09/01/1997 - "Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity."
09/01/2003 - "Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration."
07/01/2001 - "Hypercalcemia did not occur in the clodronate group but was observed in four placebo-treated patients. "
10/15/1997 - "There is wide experience in the use of clodronate in the management of patients of hypercalcemia. "
|1.||zoledronic acid (zoledronate)
|3.||Clodronic Acid (Clodronate)
|6.||ibandronic acid (Boniva)
|7.||Etidronic Acid (HEDP)
|10.||Alendronate (Alendronate Sodium)
|1.||Drug Therapy (Chemotherapy)